Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
-
New hope for chinese lung cancer patients with rare gene mutation
Disease control OngoingThis study tests two targeted pills (encorafenib and binimetinib) in 63 Chinese adults with advanced non-small cell lung cancer that has a specific BRAF V600E gene change. Participants have not had prior treatments targeting this mutation. The main goal is to see if the combinati…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 26, 2026 08:40 UTC
-
New cell therapy targets deadly Epstein-Barr virus complications
Disease control OngoingThis study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain cancers and post-transplant complications. The goal is to see if the treatment can shrink tumors and improve survival. Particip…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug targets tough cancers with BRAF/NRAS mutations
Disease control OngoingThis study tests an experimental drug called KIN-2787, taken as a pill, in about 400 adults with advanced solid tumors (like lung cancer or melanoma) that have certain gene changes (BRAF or NRAS). The main goals are to check safety, find the best dose, and see if the drug can shr…
Phase: PHASE1 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 22, 2026 13:50 UTC